{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:52:05Z","timestamp":1791474725228,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16536-8","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T01:35:14Z","timestamp":1784079314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and internal validation of a dynamic Prealbumin\u2013Immune-Inflammation\u2013NLR Prognostic Score (PINPS) for esophageal squamous cell carcinoma treated with immune checkpoint inhibitors: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Huiping","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"3","key":"16536_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10302","key":"16536_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"5","key":"16536_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"issue":"10","key":"16536_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325.","journal-title":"JAMA"},{"issue":"3","key":"16536_CR5","doi-asserted-by":"publisher","first-page":"e28617","DOI":"10.1097\/MD.0000000000028617","volume":"101","author":"N Liu","year":"2022","unstructured":"Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. The relationship between NLR\/PLR\/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Med (Baltim). 2022;101(3):e28617.","journal-title":"Med (Baltim)"},{"issue":"23","key":"16536_CR6","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212\u201322.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"16536_CR7","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s10238-023-01035-y","volume":"23","author":"J Kou","year":"2023","unstructured":"Kou J, Huang J, Li J, Liu H, Ning B, Li Y, et al. Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta-analysis. Clin Exp Med. 2023;23(7):3895\u2013905.","journal-title":"Clin Exp Med"},{"key":"16536_CR8","doi-asserted-by":"publisher","first-page":"1219929","DOI":"10.3389\/fimmu.2023.1219929","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ma W, Qiu Z, Kuang T, Wang K, Hu B, et al. Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors. Front Immunol. 2023;14:1219929.","journal-title":"Front Immunol"},{"issue":"3","key":"16536_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351\u20137.","journal-title":"JAMA Oncol"},{"issue":"5","key":"16536_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11523-024-01084-7","volume":"19","author":"K Matsumoto","year":"2024","unstructured":"Matsumoto K, Yamamoto Y, Shiroyama T, Osarogiagbon RU, Suzuki M, Kenmotsu H, et al. Risk stratification according to baseline and early change in neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer treated with chemoimmunotherapy: a multicenter real-world study. Target Oncol. 2024;19(5):757\u201367.","journal-title":"Target Oncol"},{"issue":"3","key":"16536_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41416-020-0894-7","volume":"123","author":"G Fuc\u00e0","year":"2020","unstructured":"Fuc\u00e0 G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403\u20139.","journal-title":"Br J Cancer"},{"issue":"2","key":"16536_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0272-2712(18)30443-8","volume":"13","author":"AM Spiekerman","year":"1993","unstructured":"Spiekerman AM. Proteins used in nutritional assessment. Clin Lab Med. 1993;13(2):353\u201369.","journal-title":"Clin Lab Med"},{"issue":"4","key":"16536_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343\u20136.","journal-title":"Control Clin Trials"},{"issue":"3","key":"16536_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"issue":"4","key":"16536_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385\u201395.","journal-title":"Stat Med"},{"issue":"5","key":"16536_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","volume":"39","author":"N Simon","year":"2011","unstructured":"Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox\u2019s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1\u201313.","journal-title":"J Stat Softw"},{"issue":"4","key":"16536_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361\u201387.","journal-title":"Stat Med"},{"issue":"30","key":"16536_CR18","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381\u201397.","journal-title":"Stat Med"},{"issue":"6","key":"16536_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565\u201374.","journal-title":"Med Decis Mak"},{"issue":"1","key":"16536_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"5","key":"16536_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551\u201361.","journal-title":"Stat Med"},{"issue":"12","key":"16536_CR22","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"1\u20132","key":"16536_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1023\/A:1023949509487","volume":"52","author":"S Monti","year":"2003","unstructured":"Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn. 2003;52(1\u20132):91\u2013118.","journal-title":"Mach Learn"},{"issue":"1","key":"16536_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","volume":"162","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55\u201363.","journal-title":"Ann Intern Med"},{"issue":"4","key":"16536_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1023\/A:1026595011371","volume":"1","author":"DP MacKinnon","year":"2000","unstructured":"MacKinnon DP, Krull JL, Lockwood CM. Equivalence of the mediation, confounding and suppression effect. Prev Sci. 2000;1(4):173\u201381.","journal-title":"Prev Sci"},{"key":"16536_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1742-7622-5-2","volume":"5","author":"YK Tu","year":"2008","unstructured":"Tu YK, Gunnell D, Gilthorpe MS. Simpson\u2019s Paradox, Lord\u2019s Paradox, and Suppression Effects are the same phenomenon\u2014the reversal paradox. Emerg Themes Epidemiol. 2008;5:2.","journal-title":"Emerg Themes Epidemiol"},{"issue":"13","key":"16536_CR27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/sim.9717","volume":"42","author":"N Hartman","year":"2023","unstructured":"Hartman N, Kim S, He K, Kalbfleisch JD. Pitfalls of the concordance index for survival outcomes. Stat Med. 2023;42(13):2179\u201390.","journal-title":"Stat Med"},{"key":"16536_CR28","doi-asserted-by":"publisher","first-page":"15393","DOI":"10.2147\/JIR.S547500","volume":"18","author":"X Liu","year":"2025","unstructured":"Liu X, Ren S, Li X, Wang L, Wang S, Chang J, et al. Prognostic value of inflammatory and nutritional markers in advanced esophageal squamous cell carcinoma treated with immunotherapy: a retrospective cohort study. J Inflamm Res. 2025;18:15393\u2013408.","journal-title":"J Inflamm Res"},{"key":"16536_CR29","doi-asserted-by":"publisher","first-page":"1617681","DOI":"10.3389\/fimmu.2025.1617681","volume":"16","author":"Q Zhao","year":"2025","unstructured":"Zhao Q, Wang L, Yang X, Feng J, Chen Q. Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy. Front Immunol. 2025;16:1617681.","journal-title":"Front Immunol"},{"issue":"1","key":"16536_CR30","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1186\/s12885-024-13298-z","volume":"24","author":"X Cheng","year":"2024","unstructured":"Cheng X, Meng F, Wang R, Gong C, Tang B, Li H, et al. Prognostic value of immuno-inflammatory biomarkers in esophageal squamous cell carcinoma patients receiving immunotherapy combined with chemoradiotherapy and its association with immuno-genomic landscape. BMC Cancer. 2024;24(1):1518.","journal-title":"BMC Cancer"},{"issue":"2","key":"16536_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1198\/000313005X41337","volume":"59","author":"L Friedman","year":"2005","unstructured":"Friedman L, Wall M. Graphical views of suppression and multicollinearity in multiple linear regression. Am Stat. 2005;59(2):127\u201336.","journal-title":"Am Stat"},{"issue":"4","key":"16536_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3102\/1076998619825679","volume":"44","author":"Y Kim","year":"2019","unstructured":"Kim Y. The causal structure of suppressor variables. J Educ Behav Stat. 2019;44(4):367\u201389.","journal-title":"J Educ Behav Stat"},{"issue":"2","key":"16536_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1207\/s15327906mbr3902_7","volume":"39","author":"DL Paulhus","year":"2004","unstructured":"Paulhus DL, Robins RW, Trzesniewski KH, Tracy JL. Two replicable suppressor situations in personality research. Multivar Behav Res. 2004;39(2):303\u201328.","journal-title":"Multivar Behav Res"},{"issue":"2","key":"16536_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153\u201366.","journal-title":"Cell Metab"},{"issue":"3","key":"16536_CR35","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1084\/jem.162.3.930","volume":"162","author":"G Ramadori","year":"1985","unstructured":"Ramadori G, Sipe JD, Dinarello CA, Mizel SB, Colten HR. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med. 1985;162(3):930\u201342.","journal-title":"J Exp Med"},{"issue":"11","key":"16536_CR36","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493\u2013503.","journal-title":"Lancet Oncol"},{"issue":"8","key":"16536_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/CJI.0b013e3182a802cf","volume":"36","author":"L Lu","year":"2013","unstructured":"Lu L, Pan K, Zheng HX, Li JJ, Qiu HJ, Zhao JJ, et al. IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival. J Immunother. 2013;36(8):451\u20138.","journal-title":"J Immunother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16536-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:41Z","timestamp":1791471761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16536-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16536"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16536-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Fudan University Shanghai Cancer Center (Ethics Approval No. 2603-Exp392). The requirement for individual informed consent was waived by the Institutional Review Board due to the retrospective nature of the study. This study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1209"}}